Effect of Immunomodulators Combined with Compound Ipratropium Bromide Solution for Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease
Objective:To investigate the effect of immunomodulators combined with Compound Ipratropium Bromide Solution for Inhalation in the treatment of chronic obstructive pulmonary disease(COPD).Method:A total of eighty COPD patients who were treated in the Respiratory Department of Shandong Qingzhou Rongjun Hospital from January 2017 to January 2019 were selected,they were divided into a control group(Compound Ipratropium Bromide Solution for Inhalation)and an observation group(combined with immunomodulators)by random number table method,with 40 cases in each group.The clinical efficacy,inflammatory factors[high-sensitivity C reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),procalcitonin(PCT)],lung function[peak expiratory flow(PEF),maximal voluntary ventilation(MVV),forced expiratory volume at 1 second to predicted value(FEV1%pred)],airway mucus hypersensitivity[Toll like receptor 4(TLR4),sputum wet dry density,mucin 5AC(MUC5AC)]and incidence of adverse reactions of the two groups were compared.Result:The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).Before treatment,there were no statistically significant differences in inflammatory factors between the two groups(P>0.05);after treatment,hs-CRP,TNF-α and PCT of the two groups were decreased compared to those before treatment,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Before treatment,there were no statistically significant differences in lung function indicators between the two groups(P>0.05);after treatment,PEF,MVV,and FEV1%pred in both groups were increased compared to those before treatment,and those in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).Before treatment,there were no statistically significant differences in the high secretion of airway mucus between the two groups(P>0.05);after treatment,TLR4 in both groups were decreased,and that in the observation group was lower than that in the control group,the differences were statistically significant(P<0.05),the dry wet ratio of sputum and MUC5AC were decreased,and those in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion:The combination of immunomodulators and Compound Ipratropium Bromide Solution for Inhalation is effective in treating COPD.It can improve lung function,inhibit inflammatory reactions,alleviate airway mucus hypersensitivity,and has high safety.
国家科技期刊平台
NSTL
万方数据
